This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Early Savings Deadline Expires In:

  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event
May 9-12, 2022Hynes Convention Center, Boston

Systems Oncology


Systems Oncology is developing a new class of multimodal RNA therapeutics that simultaneously silence the right combination of disease targets with a single RNA molecule to improve outcomes and combat emerging drug resistance. Our ArromerTM platform is used to digitally engineer and rapidly produce self-delivering therapeutics which are directed to specific tissues with unprecedented precision and accuracy. We are focused on building a pipeline of drug products in oncology, yet our multimodal RNA therapeutics platform can be harnessed to transform outcomes for any complex polygenic disease.

We're bringing you

  • ROOM 205C: Arromer: Receptor Directed Delivery for Ultra-precise RNAi Multi-targeting